Measurement · Operating decision guide
AI value creation in a private-equity portfolio
Otomat editorial · Revised · Original edition 16 March 2026
Separate sponsor priorities, company economics and GP efficiency; test replication without pooling client data or promising an exit premium.
Keep the units of value separate
A sponsor may care about portfolio value, while a company manager controls a workflow and its budget. Agree whose result is measured. GP efficiency, portfolio-company operating improvement and exit valuation are different claims with different evidence requirements.
Do not add hypothetical company gains to a fund return forecast without timing, ownership, cost and attribution. An exit multiple premium is not an automatic consequence of introducing AI. Buyers may discount brittle dependencies or unproven results.
Choose a workflow with an accountable company owner
Map one investment-thesis priority to a process constraint and a measurement contract. Check management bandwidth and data access before a build. Sponsor oversight can help remove obstacles, but does not substitute for local acceptance or permission.
| Workstream | Accountable decision owner | Evidence before advancing | If evidence is missing |
|---|---|---|---|
| GP internal workflow | GP process owner and budget holder | Task baseline, permitted sources and acceptance test within the GP | Hold the workflow; do not assign GP efficiency to portfolio-company EBITDA |
| Portfolio-company workflow | Company executive, workflow owner and finance reviewer | Local baseline, data rights, management capacity, full cost and accepted task results | Resolve ownership and rights before building; leave financial benefit unaccepted |
| Reuse in another company | Receiving company owner and technical maintainer | Permission to reuse the method; fresh local task sample, integrations and acceptance | Do not scale an untested system or pool company data by default |
| Exit or valuation narrative | Company management and sponsor deal team | Sustained operating evidence, transferable rights, costs and buyer-specific diligence | Do not assert an AI valuation premium or treat a forecast as realized benefit |
Replicate the method, requalify the system
Reuse generic evaluation methods and architecture patterns when rights permit. Do not pool company data, embeddings, feedback or confidential operating knowledge by default. Each company needs its own authorization, fresh task sample and acceptance record. Track migration effort and local exceptions so replication cost remains visible.
Use the working tools
Blank templates are ungated. Adapt them to the workflow; inputs are not submitted.
Sources and limits
These are Otomat’s proposed operating methods and original decision artifacts. External references inform risk management; they do not certify this method or establish client results. Linked sources were selected for this review; their live revision dates may change.
For anonymous documentation and proposal patterns, see delivery evidence and its boundaries.
Related decisions
Bring a workflow to the discussion
Share the business goal and constraints through the mandate process. Do not send sensitive production data in the initial brief.
Scope an Operating Mandate